ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Reports and Filings

  • Uncategorised
    Article Count:  9
  • Our Science

    Our portfolio approach gives us the freedom to pursue a wider range of technologies, maximizing opportunities for growth and value creation. We develop new medical innovations we believe can make a significant clinical impact in improving the health of patients.

    • Our portfolio covers a range of technologies that focus on different therapeutic areas, which helps us to mitigate risk and create and build value.
    • Our scientists collaborate in a way that facilitates knowledge sharing across different technologies and therapeutic areas.
    Article Count:  0
    • Our Key Platforms
      Article Count:  4
    • Our Publications
      Article Count:  0
      • Brain Tumor Stem Cell Targeting
        Article Count:  2
      • Borg Peptide Solid Surface Interface
        Article Count:  5
      • Treatments for Inflammation
        Article Count:  5
      • AB569
        Article Count:  4
  • Our Team

    We have the expertise to advance and build value in our technologies from discovery to commercialization.

    • Our management team and Board of Directors have significant experience bringing technologies to human trial.
    • We also engage industry experts and consultancies to ensure we bring best-in-class talent and experience to advance and build value in our technologies. 
    Article Count:  0
    • Our Principal Scientists
      Article Count:  4
    • Our Management
      Article Count:  1
  • Investor Hub

    We are ruthless in our evaluation of preclinical technologies, focusing on opportunities that have the potential to meet unmet medical needs and present a short path to value creation; we only pursue the best.

    • We follow a rigorous screening process to evaluate our investments in preclinical technologies. 
    • We only pursue the technologies that meet our strict criteria, which includes a strong intellectual property position and commercial potential. 
    • We only invest when we are certain the technologies meet our criteria.
    • We are focused on developing intellectual property and future revenue through patent filings and technology ownership.
    Article Count:  0
    • Fundamentals
      Article Count:  2
      • Press Releases
        Article Count:  1
        • Press Releases 2011
          Article Count:  11
        • Press Releases 2012
          Article Count:  7
        • Press Releases 2013
          Article Count:  8
        • Press Releases 2014
          Article Count:  8
        • Press Releases 2015
          Article Count:  15
        • Press Releases 2016
          Article Count:  12
        • Press Releases 2017
          Article Count:  13
        • Press Releases 2018
          Article Count:  14
        • Press Releases 2019
          Article Count:  9
        • Press Releases 2020
          Article Count:  29
    • Reports and Filings
      Article Count:  5

Recent News

January 5th 2021

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Read More
December 29th 2020

Arch Biopartners Closes Non-Brokered Private Placement

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Reports and Filings
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us